; Latouche et al., 1989) . Recently, several studies have demonstrated independently expression of the GnRH receptor In an attempt to resolve the apparent controversy in gene in human ovarian tissue (Kakar et al., 1992; Peng et al. , the observed effects of gonadotrophin-releasing hormone 1994; Minaretzis et al., 1995b; Fraser et al., 1996). Based on (GnRH) analogues on the ovary, conventional binding these results, we postulated that any direct ovarian effects of studies were conducted with a GnRH agonist and an GnRH analogues may not only on affinity type, but also on antagonist in various ovarian tissues to demonstrate the timing of the appearance of GnRH receptors. In an attempt possible GnRH receptor binding. In human luteinized to resolve the apparent controversy in observed direct effects, granulosa cells derived from unstimulated in-vitro fertilizawe conducted conventional binding studies in human pretion cycles, high affinity receptor binding was present in ovulatory non-luteinized follicles and in luteinized follicular 17 out of 24 patients, while binding was not observed aspirates with a GnRH agonist and antagonist so as to estimate in any of the six pre-ovulatory follicles removed during affinity type and the timing of the appearance of possible abdominal surgery. Apparently contradictory observations GnRH receptor binding. on the direct ovarian effects of GnRH analogues may be the result of the intermittent presence of high affinity GnRH receptors. Our observations indicate that in the Materials and methods human, high affinity ovarian GnRH receptors are present antagonist/granulosa cells/human ovary menstrual cycles of~28 days; five of the women were undergoing hysterectomy for various benign gynaecological diseases [uterine myomas (n ϭ 2), pelvic pain (n ϭ 3)], and one a Burch operation with sterilization. Surgery was planned such that all the women were
1989; Latouche et al., 1989) . Recently, several studies have demonstrated independently expression of the GnRH receptor In an attempt to resolve the apparent controversy in gene in human ovarian tissue (Kakar et al., 1992; Peng et al. , the observed effects of gonadotrophin-releasing hormone 1994; Minaretzis et al., 1995b; Fraser et al., 1996) . Based on (GnRH) analogues on the ovary, conventional binding these results, we postulated that any direct ovarian effects of studies were conducted with a GnRH agonist and an GnRH analogues may not only on affinity type, but also on antagonist in various ovarian tissues to demonstrate the timing of the appearance of GnRH receptors. In an attempt possible GnRH receptor binding. In human luteinized to resolve the apparent controversy in observed direct effects, granulosa cells derived from unstimulated in-vitro fertilizawe conducted conventional binding studies in human pretion cycles, high affinity receptor binding was present in ovulatory non-luteinized follicles and in luteinized follicular 17 out of 24 patients, while binding was not observed aspirates with a GnRH agonist and antagonist so as to estimate in any of the six pre-ovulatory follicles removed during affinity type and the timing of the appearance of possible abdominal surgery. Apparently contradictory observations GnRH receptor binding. on the direct ovarian effects of GnRH analogues may be the result of the intermittent presence of high affinity GnRH receptors. Our observations indicate that in the Materials and methods human, high affinity ovarian GnRH receptors are present Introduction in late follicular phase. The stage of the menstrual cycle was determined by the patients' history and confirmed by pre-operative
In the past decade substantial progress has been made in the vaginal ultrasound examinations. None of the patients used any development of gonadotrophin-releasing hormone (GnRH) medication. Examination of the ovaries did not reveal any abnormanalogues as both diagnostic and therapeutic tools. GnRH alities. Under general anaesthesia, the pre-ovulatory follicles were agonists are widely used in in-vitro fertilization (IVF) prosharply dissected and immediately snap frozen in liquid nitrogen until cedures for the prevention of premature luteinization.
further analysis.
A meta-analysis suggested that the use of GnRH agonists in IVF procedures results in more and better quality oocytes Collection of human luteinized granulosa cells (Hughes et al., 1992 control for the human luteinized follicular aspirates. These rats were kept under the same conditions as the adult female rats, but were treated with 100 µl (5 mg/ml saline) diethylstilbestrol (Organon, Oss, analogue of either antide or buserelin were added to half of the tubes The Netherlands) for 3 days and killed by an overdose of ether in a total volume of 500 µl. In each assay, D-Tyr-antide and buserelin inhalation. Ovaries were dissected and the follicles were punctured;
were tested in duplicate. the cells collected were stored at -20°C until use.
Incubation was terminated after 90 min at 4°C for buserelin and after 24 h at 4°C for D-Tyr-antide by centrifugation for 15 min at Peptides 12 000 g. Subsequently radioactivity in the pellets was counted. The The GnRH antagonist antide and D-Tyr-antide for iodination were specific binding was calculated (i.e. total binding -non-specific kindly supplied by Ares Serono (Geneva, Switzerland). The GnRH binding) and expressed as a percentage of the total counts added. agonist buserelin was generously donated by Hoechst Holland NV The specific activity, as determined by self-displacement (Clayton, (Amsterdam, The Netherlands). Radio-iodinated NaI was purchased 1983) in human granulosa cells, was 606 µCi/mg for D-Tyr-antide from Amersham (Amersham, UK).
and 891 µCi/mg for buserelin. The counting efficiency of the gamma spectrometer was 75%. Maximal binding ability was established by Radio-iodination of GnRH analogues adding excess rat pituitary or ovarian homogenate or pooled granulosa Buserelin was radio-iodinated by the hypochloride method (Redshaw cells to 3000 c.p.m. of the iodinated peptides. Maximal binding was and Lynch, 1974) and purified using a QAE Sephadex column (Hazum, 20-40% for D-Tyr-antide and 15-35% for buserelin. The K a value 1981). D-Tyr-antide was radio-iodinated by the lactoperoxidase method was calculated using a computerized Scatchard analysis of saturation (Copeland et al., 1979; Li et al., 1994) and purified using a Sephadex assays (Munson and Rodbard, 1979) . Because of the limited avail-G25 column.
ability of human granulosa cells, the K a values were estimated in pooled material. Preparation of human pre-ovulatory follicles and rat pituitaries and ovaries After thawing, the pre-ovulatory follicles were homogenized in Human pre-ovulatory follicles bovine serum albumin (BSA), pH 7.4] using 1 ml incubation buffer per half a human follicle. In parallel, the rat pituitaries and rat ovaries No binding was found in any of the six human pre-ovulatory were thawed and homogenized in the same buffer using 1 ml per follicles with either D-Tyr-antide or buserelin (Fisher's exact pituitary and 1 ml per two ovaries. test: 95% confidence interval 54.07-100.00%).
The material was centrifuged for 5 min at 225 g. The supernatant of the first spin was centrifuged for 15 min at 12 000 g. The pellet
Human follicular aspirate of the second spin was resuspended with the buffer; 250 µl of the Specific binding in the follicular aspirate was found in a suspension were used containing the equivalent of one quarter of a significant number of patients (17/24) ( Table I) 
Preparation of human luteinized granulosa cells and rat

Rat tissue granulosa cells
As expected, specific binding of rat pituitaries, ovaries and After thawing, 2 ml of the follicular aspirates were added to 1 ml of granulosa cells could be detected in all samples with values the buffer and centrifuged for 15 min at 225 g. Subsequently, the of 24, 20 and 13% respectively with D-Tyr-antide and of 10, supernatant was centrifuged for 30 min at 12 000 g, after which the 5 and 6% respectively with buserelin (Table II) .
pellet was resuspended in the assay buffer and 250 µl (810 mg DNA/ ml) were used for the binding assay.
Binding characteristics The binding characteristics of the GnRH analogues with the
Binding assay procedure various homogenates are given in Table III affinity binding sites were demonstrated in rat pituitaries, rat or 2.5ϫ10 -11 M iodinated buserelin (10 000 c.p.m.) were added to all the tubes. To determine non-specific binding, 2 µg/100 µl GnRH ovaries, pooled rat granulosa cells and pooled human granulosa (Clayton et al., 1979; Seguin et al., 1982) and explain the agonists (Wickings et al., 1990) .
Human granulosa 3.6 2.7
Indeed, conflicting data exist on the presence of GnRH receptors in primate ovarian tissue. Latouche et al. (1989) showed GnRH agonist binding sites with high affinity in the cells. The binding capacities (receptor concentrations) for granulosa of a single human pre-ovulatory follicle. Bramley human granulosa cells were 74 fmol/mg DNA for D-Tyr-antide et al. (1985) demonstrated low affinity binding in mid-luteal and 61 fmol/mg DNA for buserelin. corpora lutea. However, no GnRH receptor binding was Displacement curves of iodinated D-Tyr-antide and iodinated demonstrated in corpora lutea by Clayton and Huhtaniemi buserelin are given in Figure 1 . (1982) , while another study showed the presence of specific binding sites for GnRH and its analogues in human luteal Binding and IVF and embryo transfer outcome homogenates (Popkin et al., 1983) . Fraser et al. (1996) The absence or presence of binding was not significantly demonstrated low levels of expression of GnRH receptor related to any of the IVF and embryo transfer outcome mRNA with in-situ hybridization in human corpora lutea. In parameters such as fertilization rate (Fisher's exact test: P ϭ addition, Kakar et al. (1992) demonstrated, by the polymerase 0.6225) or pregnancy rate (P ϭ 0.5165). In all seven cases chain reaction amplification technique, the presence of cDNA with no binding oocytes were obtained, whereas no oocytes coding for the human GnRH receptor in some samples of could be obtained in six out of the 17 subjects in whom human ovarian tissue. Even more recently, GnRH receptor specific binding was demonstrated (P ϭ 0.13).
mRNA has been demonstrated both in human luteinized granulosa cells (Peng et al., 1994) and in human ovarian Discussion homogenates across different functional stages of the menstrual cycle, implying that multiple ovarian compartments may Our study shows that specific GnRH agonistic and antagonistic binding is present in human luteinized granulosa cells. The K a express GnRH receptors (Minaretzis et al., 1995b) . Our data indicate, however, the temporary presence of values indicate high affinity binding sites, comparable with the binding that we measured in rat pituitary, ovary and functional GnRH binding in human ovarian tissue, predominantly around ovulation. This temporary presence would largely granulosa cells. In contrast, no binding was measured in homogenates of pre-ovulatory follicles.
explain the wide variety of results of experiments testing the direct ovarian effects of GnRH analogues. Controversies exist with respect to the direct ovarian effects of GnRH agonists and antagonists in vitro. The many differAll pre-ovulatory follicles were collected under general anaesthesia, and follicular aspiration was carried out under local ences in observation with respect to the production of major ovarian hormones indicate that a variety of factors may be anaesthesia. Therefore the theoretical possibility of anaesthetic conditions influencing GnRH receptor binding cannot be involved, such as type and dose of the analogue (Bussenot et al., 1993) , ovarian cell types and the hormonal pretreatment excluded. There are, however, no literature data to support this. Therefore the question as to what regulates expression of of these cells (Casper et al., 1982; Tureck et al., 1982; Birnbaumer et al., 1985) . The most important determinant, the GnRH receptor remains. GnRH itself increased the amount of mRNA in precultured however, is probably the presence or absence of a GnRH human granulosa luteal cells (Peng et al., 1994) . The same regulated physiological mechanism that may be influenced pharmacologically. The effects of stimulation or inhibition of report showed that in cultured human granulosa luteal cells GnRH receptor gene expression is down-regulated by prothe human ovarian GnRH receptor need to be elucidated further. In view of the likelihood of regulation by GnRH itself, longed exposure to HCG. Previous studies in the rat ovary have shown that the injection of HCG caused a 60% loss of more prudence should be applied to the use of GnRH agonist, and in the near future the GnRH antagonist, immediately prior GnRH receptor (Harwood et al., 1980) . Whitelaw et al. (1995) observed that the administration of follicle stimulating hormone to or during the time of ovulation. or human menopausal gonadotrophin to hypophysectomized female rats enhanced the expression of GnRH receptor mRNA.
